We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Colon Cancer Risk Traced To Common Ancestor

By Biotechdaily staff writers
Posted on 14 Jan 2008
A married couple who sailed from England to America around 1630 may be the ancestors of hundreds of people alive today who are at risk for a hereditary form of colon cancer.

Researchers from the Huntsman Cancer Institute (HCI) at the University of Utah (Salt Lake City, USA) studied two large families, one in Utah (USA) and one in New York (USA), that carry a specific genetic mutation that causes a condition called attenuated familial adenomatous polyposis (AFAP). More...
Without proper clinical care, people with the AFAP mutation have a greater than two in three risk of colon cancer by age 80, compared to about one in 24 for the general population. The researchers discovered that the two families share common ancestors, a couple who came to America from England in the 1630s, about the time of the Pilgrims.

The Utah family in this study has more than 7,000 descendants spanning nine generations recorded in the Utah population database (UPDB). Members of this one family account for 0.15% of all colorectal cancers reported in Utah from 1966 to 1995. Based on that percentage, researchers expected to see eight cases of colon cancer from this one family among the over 5,000 reported between 1996 and 2003; but after previous research identified this family as affected by AFAP, aggressive education and clinical intervention resulted in only one mutation carrier in the family being diagnosed with colon cancer during those years. The study was published in the January 2008 issue of the journal Clinical Gastroenterology and Hepatology.

"The fact that this mutation can be traced so far back in time suggests that it could be carried by many more families in the United States than is currently known,” said lead author Deborah Neklason, Ph.D. "In fact, this founder mutation might be related to many colon cancer cases in the United States.”

Clinical recognition of AFAP can be difficult because AFAP-related colon cancer develops on average around 50 years of age, as do sporadic (non-hereditary) colon cancers. About one-third of people with AFAP also have only a few polyps, again similar to that for sporadic colon cancer, and they may also have a limited family history.


Related Links:
University of Utah

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.